SL
RVMD icon

Salomon & Ludwin’s Revolution Medicines RVMD Stock Holding History

Salomon & Ludwin’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.69K Hold
41
– – ﹤0.01% 1694
2026
Q1 		$4.06K Hold
41
– – ﹤0.01% 1812
2025
Q4 		$3.21K Hold
41
– – ﹤0.01% 1916
2025
Q3 		$1.92K Buy
+41
New +$1.6K ﹤0.01% 1983

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Salomon & Ludwin's RVMD Position: Q2 2026 in Review

Salomon & Ludwin held its Revolution Medicines (RVMD) position steady in Q2 2026 at 41 shares worth $7.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1694.

Salomon & Ludwin first reported a position in RVMD in Q3 2025 and has held it in 4 quarters since. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Salomon & Ludwin held 41 shares of Revolution Medicines worth $7.69K as of Q2 2026.
  • Salomon & Ludwin left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1694 holding.
  • Salomon & Ludwin first reported a position in Revolution Medicines in Q3 2025 and has held it in 4 quarters since.
  • 688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.